Lack of Clinical Benefit of Interferon β-1a Among Patients With Severe Acute Respiratory Distress Syndrome
Open Access
- 25 February 2020
- journal article
- editorial
- Published by American Medical Association (AMA) in JAMA
- Vol. 323 (8), 713-715
- https://doi.org/10.1001/jama.2019.22524
Abstract
In acute respiratory distress syndrome (ARDS), the alveolar-capillary units are disrupted, with lung endothelial and epithelial injury resulting in exudative puThis publication has 15 references indexed in Scilit:
- Integrating molecular pathogenesis and clinical translation in sepsis-induced acute respiratory distress syndromeJCI Insight, 2019
- Extracellular adenosine‐induced Rac1 activation in pulmonary endothelium: Molecular mechanisms and barrier‐protective roleJournal of Cellular Physiology, 2017
- Extremes of Interferon-Stimulated Gene Expression Associate with Worse Outcomes in the Acute Respiratory Distress SyndromePLOS ONE, 2016
- The effect of intravenous interferon-beta-1a (FP-1201) on lung CD73 expression and on acute respiratory distress syndrome mortality: an open-label studyThe Lancet Respiratory Medicine, 2013
- Acute Respiratory Distress SyndromeJAMA, 2012
- Immunomodulatory functions of type I interferonsNature Reviews Immunology, 2012
- Bacteria-Specific Neutrophil Dysfunction Associated with Interferon-Stimulated Gene Expression in the Acute Respiratory Distress SyndromePLOS ONE, 2011
- The Type I Interferon Signaling Pathway Is a Target for Glucocorticoid InhibitionMolecular and Cellular Biology, 2010
- Causation and Causal Inference in EpidemiologyAmerican Journal of Public Health, 2005
- Regulation of Endothelial CD73 by Adenosine: Paracrine Pathway for Enhanced Endothelial Barrier FunctionThe Journal of Immunology, 2000